STING1 and neoplasm: DMXAA remains a useful STING agonist for proof-of-concept studies in mice, and whilst DMXAA has been tested in another murine mesothelioma model syngeneic to Balb/c mice, i.e. AB12 (12), several questions remained unanswered for mesothelioma including: identifying an optimal treatment regimen; providing a deeper understanding of changes to tumor antigen presentation in-vivo; measuring changes to CTL hierarchical responses; and addressing the potential for combination with other immunotherapies.